PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC research hub

Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

This study looks at a new drug combination, acasunlimab and pembrolizumab, for a type of lung cancer that has spread or is advanced. It compares this combination to a standard chemotherapy, docetaxel, in people who have already had certain other treatments.